75677-08-6Relevant academic research and scientific papers
A family of stilbene-ethers as photolabile protecting groups for primary alcohols offers controlled deprotection based on choice of wavelength
Ho, Jinn-Hsuan,Lee, Ya-Wen,Chen, Ying-Zhe,Chen, Pin-Sian,Liu, Wei-Qi,Ding, Yi-Shun
, p. 7325 - 7332 (2013/08/23)
A novel stilbene-ether type of photolabile protecting group (PPG) for hydroxyl group has been developed. It contains a stable aryl ether group in the protected form and can be deprotected by acid-catalyzed photorearrangement under 300-nm irradiation. The selective deprotection has also been achieved by irradiation of the mixture of 4-alkoxystilbene and 2-(4-alkoxystyryl)furan at 365 nm.
NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF
-
Page/Page column 22, (2011/11/12)
The present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and the uses thereof. More specifically, the present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and a pharmaceutical composition comprising the same. The novel thiazolidinedione derivatives of formula (I) according to the present invention can be effectively used for the prevention or treatment of cardiovascular disease, gastrointestinal disease and renal disease by inhibiting the activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) that decomposes prostaglandins as well as useful for the prevention of hair loss and the stimulation of hair growth, and osteogenic stimulation and wound healing.
N-BENZYL OXAZOLIDINONES AND RELATED HETEROCYCLEIC COMPOUNDS AS POTENTIATORS OF GLUTAMATE RECEPTORS
-
Page/Page column 78, (2009/03/07)
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. The compounds are active as potentiators of glutamate receptors, in particular mGluR2.
N-substituted imidazol derivative
-
, (2008/06/13)
The present invention is to provide novel imidazole derivatives effectual as an antihyperlipemic agent and therapeutic and preventive drugs for arteriosclerosis, and to provide methods for manufacturing the said derivatives. More particularly, the present invention is directed to the compounds represented by the following general formula [I]; STR1 wherein R1 is hydrogen or lower alkyl, n is 0 or 1, X is N-r1 wherein r1 is hydrogen or lower alkyl, O, S, SO, SO2, CH2, CH(CH3), CONH or C(r2)=NO wherein r2 is hydrogen or lower alkyl, m is 0 or an integer of from 1 to 12, and A is methyl or a group represented by the following general formula; STR2 wherein Y is N-r3 wherein r3 is hydrogen or lower alkyl, N(r4)SO2 wherein r4 is hydrogen or lower alkyl, O, S, SO, SO2, CH2, CH(CH3), CONH or C(r5)=NO wherein r5 is hydrogen or lower alkyl, R2 is a halogen, a lower alkyl, a lower alkoxy, a cycloalkyl or COOr6 wherein r6 is hydrogen or a lower alkyl, and l is 0, 1, 2 or 3, however, m denotes an integer of from 6 to 9 when A is methyl, or m denotes 0 or an integer of from 1 to 6 when A is a group represented by the following general formula; STR3 and X and Y are each independently CH2 when m is 0, the pharmaceutically-acceptable salts thereof and methods for manufacturing the said compounds and the pharmaceutically-acceptable salts thereof.
N-(phenylether-substituted benzyl)alkanediamines
-
, (2008/06/13)
Novel N-(substituted benzyl)alkanediamines are prepared which are useful for the prevention and inhibition of viral infections.
